Long-term Efficacy of Siponimod Treatment for up to 5 Years in Patients with Secondary Progressive Multiple Sclerosis: Analysis of the EXPAND Extension Study

被引：0

作者：

Kappos, L. ^{[1
,2
,3
,4
,5
]}

Giovannoni, G. ^{[6
]}

Gold, R. ^{[7
]}

Fox, R. J. ^{[8
]}

Vermersch, P. ^{[9
]}

Benedict, R. H. B. ^{[10
]}

Bar-or, A. ^{[11
,12
]}

Rouyrres, N. ^{[13
]}

Piani-Meier, D. ^{[13
]}

Ritter, S. ^{[14
]}

Kilaru, A. ^{[13
]}

Dahlke, F. ^{[13
]}

Karlsson, G. ^{[13
]}

Cree, B. A. C. ^{[15
]}

机构：

[1] Univ Hosp, Dept Med, Neurol Clin & Policlin, Basel, Switzerland

[2] Univ Hosp, Dept Clin Res, Neurol Clin & Policlin, Basel, Switzerland

[3] Univ Hosp, Dept Biomed, Neurol Clin & Policlin, Basel, Switzerland

[4] Univ Hosp, Dept Biomed Engn, Neurol Clin & Policlin, Basel, Switzerland

[5] Univ Basel, Basel, Switzerland

[6] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England

[7] Ruhr Univ Bochum, Dept Neurol, St Josef Hosp, Bochum, Germany

[8] Cleveland Clin, Neurol Inst, Mellen Ctr Treatment & Res Multiple Sclerosis, Cleveland, OH 44106 USA

[9] Univ Lille, CHU Lille, FHU Imminent, INSERM,U995, Lille, France

[10] SUNY Buffalo, Dept Neurol, Buffalo, NY USA

[11] Univ Penn, Perelman Sch Med, Ctr Neuroinllammat & Expt Therapeut, Philadelphia, PA 19104 USA

[12] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA

[13] Novartis Pharma AG, Basel, Switzerland

[14] Novartis Pharmaceut, E Hanover, NJ USA

[15] Univ Calif San Francisco, Dept Neurol, UCSE Weill Inst Neurosci, San Francisco, CA USA

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EPR2128

引用

页码：337 / 337

页数：1

共 50 条

[1] Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years
Cree, Bruce A. C.
Arnold, Douglas L.
Fox, Robert J.
Gold, Ralf
Vermersch, Patrick
Benedict, Ralph H. B.
Bar-Or, Amit
Piani-Meier, Daniela
Rouyrre, Nicolas
Ritter, Shannon
Kilaru, Ajay
Karlsson, Goeril
Giovannoni, Gavin
Kappos, Ludwig
[J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (10) : 1591 - 1605
[2] Long-term Efficacy and Safety of Siponimod in Patients with SPMS: EXPAND Extension Analysis Up to 5 Years
Kappos, Ludwig
Giovannoni, Gavin
Gold, Ralf
Fox, Robert J.
Vermersch, Patrick
Benedict, Ralph H. B.
Bar-Or, Amit
Rouyrre, Nicolas
Meier, Daniela Piani
Ritter, Shannon
Kilaru, Ajay
Dahlke, Frank
Karlsson, Goeril
Cree, Bruce A. C.
[J]. NEUROLOGY, 2020, 94 (15)
[3] The EXPAND study results: Efficacy of siponimod in secondary progressive multiple sclerosis
Vermersch, P.
Bar-Or, A.
Cree, B.
Fox, R.
Giovannoni, G.
Gold, R.
Arnould, S.
Wallstroem, E.
Sidorenko, T.
Wolf, C.
Dahlke, F.
Kappos, L.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 44 - 44
[4] Efficacy of Siponimod in secondary progressive multiple sclerosis patients with active disease: the EXPAND study subgroup analysis
Gold, R.
Kappos, L.
Bar-Or, A.
Vermersch, P.
Giovannoni, G.
Fox, R.
Rouyrre, N.
Karlsson, G.
Cree, B. A. C.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 380 - 381
[5] The EXPAND study results: Safety and tolerability of siponimod in patients with secondary progressive multiple sclerosis
Giovannoni, G.
Bar-or, A.
Cree, B.
Fox, R.
Gold, R.
Vermersch, P.
Pohlmann, H.
Wallstrom, E.
Wolf, C.
Dahlke, F.
Sidorenko, T.
Kappos, L.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 495 - 495
[6] Analyses of the effect of baseline age on the efficacy and safety of siponimod in patients with active secondary progressive multiple sclerosis from the EXPAND study
Hua, L. H.
Bar-Or, A.
Lublin, F. D.
Meng, X.
Cox, G. M.
Cree, B. Ac
Fox, R. J.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 551 - 552
[7] Safety and efficacy of siponimod in patients with active secondary progressive multiple sclerosis identifying as Hispanic from the phase 3 EXPAND study
Cohan, S.
Hua, L. H.
Bar-Or, A.
Lublin, F. D.
Meng, X.
Cox, G. M.
Coyle, P. K.
Fox, R. J.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 590 - 591
[8] Effect of Siponimod on Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Phase 3 EXPAND Study Subgroup Analysis
Benedict, Ralph
Fox, Robert
Tomic, Davorka
Cree, Bruce
Vermersch, Patrick
Giovannoni, Gavin
Bar-Or, Amit
Gold, Ralf
Ritter, Shannon
Karlsson, Goeril
Wolf, Christian
Kappos, Ludwig
[J]. NEUROLOGY, 2019, 92 (15)
[9] MODELLING LONG-TERM HEALTH BENEFITS OF SIPONIMOD IN ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS IN PORTUGAL
Silva, C.
Bandeiras, C.
Laires, P. A.
[J]. VALUE IN HEALTH, 2020, 23 : S627 - S627
[10] Long-term Effect of Siponimod on MRI Outcomes in SPMS: Analyses from the EXPAND Study up to 5 Years
Arnold, Douglas L.
Kappos, Ludwig
Vermersch, Patrick
Gold, Ralf
Bar-Or, Amit
Giovannoni, Gavin
Cree, Bruce A. C.
Meier, Daniela Piani
Ritter, Shannon
Karlsson, Goeril
Dahlke, Frank
Hach, Thomas
Fox, Robert J.
[J]. NEUROLOGY, 2021, 96 (15)

← 1 2 3 4 5 →